Statins | Search Results | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Search Results for 'Statins'

NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases – Series A, Volume 5

Posted in on June 7, 2022|

Original Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in […]

Read Full Post »

Hypertriglyceridemia: Evaluation and Treatment Guideline

Posted in Biomarkers & Medical Diagnostics, Biomedical Measurement Science, Cardiovascular Pharmacogenomics, Cardiovascular Research, Chemical Biology and its relations to Metabolic Disease, Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH), Clinical Diagnostics, Clinical Genomics, Diabetes Mellitus, Disease Biology, Endocrine Diseases, Epigenetics and Cardiovascular Risks, Frontiers in Cardiology and Cardiovascular Disorders, Lipid metabolism, Liver & Digestive Diseases Research, Metabolism, Myocardial Metabolism, Nutrition, Nutrition Disorders, Nutritional Supplements: Atherogenesis, lipid metabolism, Obesity, Origins of Cardiovascular Disease, Pancreatic adenocarcinoma classifier, Pancreatic cancer, Population Health Management, Population Health Management, Genetics & Pharmaceutical, tagged Cardiovascular disease, Cholesterol, diet, hypertriglyceridemia, life style, pancreatitis, triglycerides on January 22, 2019| 1 Comment »

Hypertriglyceridemia: Evaluation and Treatment Guideline Reporter and Curator: Dr. Sudipta Saha, Ph.D. Severe and very severe hypertriglyceridemia increase the risk for pancreatitis, whereas mild or moderate hypertriglyceridemia may be a risk factor for cardiovascular disease. Individuals found to have any elevation of fasting triglycerides should be evaluated for secondary causes of hyperlipidemia including endocrine […]

Read Full Post »

SAR-Cov-2 is probably a vasculotropic RNA virus affecting the blood vessels: Endothelial cell infection and endotheliitis in COVID-19

Posted in COVID-19, Population Health Management, Genetics & Pharmaceutical, SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus, SARS-CoV-2, Treatment Protocols for COVID-19, Virus Infective Acute Respiratory Syndrome: SARS-CoV on June 1, 2020| 4 Comments »

SAR-Cov-2 is probably a vasculotropic RNA virus affecting the blood vessels: Endothelial cell infection and endotheliitis in COVID-19 Reporter: Aviva Lev-Ari, PhD, RN – Bold face and colors are my addition From: “Dr. Larry Bernstein” <larry.bernstein@gmail.com> Reply-To: “Dr. Larry Bernstein” <larry.bernstein@gmail.com> Date: Tuesday, June 2, 2020 at 8:50 AM To: Aviva Lev-Ari <aviva.lev-ari@comcast.net> Subject: Re: […]

Read Full Post »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic

Posted in Atherogenic Processes & Pathology, Frontiers in Cardiology and Cardiovascular Disorders, Origins of Cardiovascular Disease, PCSK9 Inhibitor Therapy, Pharmacotherapy of Cardiovascular Disease, Vascular Diseases, tagged Atherosclerosis, Cholesterol, LDL, PCSK9 inhibitors, statins on December 29, 2016| Leave a Comment »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]

Read Full Post »

Perioperative Statins at Noncardiac Surgery: Survival Up, Complications Down

Posted in Perioperative Statins at Noncardiac Surgery on December 27, 2016| Leave a Comment »

Perioperative Statins at Noncardiac Surgery: Survival Up, Complications Down Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 11/26/2018 Clinical Trial: Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) A Cardio-Endo Connection selection by Dharam J. Kumbhani, MD, SM (Trial Summary); Deepak L. Bhatt, MD, MPH (Summary Reviewer) Contribution to Literature: The Statins Evaluation in Coronary […]

Read Full Post »

Live Notes from @HarvardMed Bioethics: Authors Jerome Groopman, MD & Pamela Hartzband, MD, discuss Your Medical Mind

Posted in and Bioethics, Bio-Ethics, Ethics and Leadership, Health Economics and Outcomes Research, Patient Experience, Patient Experience: Personal Memories of Invasive Medical Intervantion, Patient Outlook, Patient-centered Medicine, Prescription Drugs Costs on March 27, 2020| 1 Comment »

Live Notes from @HarvardMed Bioethics: Authors Jerome Groopman, MD & Pamela Hartzband, MD, discuss Your Medical Mind Writer: Stephen J. Williams, Ph.D. As part of the Harvard Medical School Series on Bioethics: author, clinician and professor Jerome Groopman, MD and Pamel Harzband, MD gave an online discussion of their book “Your Medical Mind”, a part […]

Read Full Post »

NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms – Series A: Volume 1

Posted in on June 6, 2022|

Original Volume One: Perspectives on Nitric Oxide in Disease Mechanisms NEW GENRE Volume One: Perspectives on Nitric Oxide in Disease Mechanisms https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-one-perspectives-on-nitric-oxide-in-disease-mechanisms-series-a-volume-1/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab) a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway

Posted in Acute Myocardial Infarction, Cardiovascular Research, Frontiers in Cardiology and Cardiovascular Disorders, Heart Failure (HF), inflammation independent of lipid levels, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, Stroke, Vascular Diseases, tagged Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS), human monoclonal antibody targeting the interleukin-1beta innate immunity pathway on April 6, 2018| Leave a Comment »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]

Read Full Post »

@Cleveland Clinic – Serial measurements of high-sensitivity C-reactive protein (hsCRP) post acute coronary syndrome (ACS) may help identify patients at higher risk for morbidity and mortality

Posted in Acute coronary syndrome, Acute Myocardial Infarction, Atherogenic Processes & Pathology, Cardiovascular Research, Frontiers in Cardiology and Cardiovascular Disorders, HTN, inflammation independent of lipid levels, Origins of Cardiovascular Disease, Pharmacotherapy of Cardiovascular Disease, Systemic Inflammatory Diseases as CVD Risk on May 5, 2019| Leave a Comment »

@Cleveland Clinic – Serial measurements of high-sensitivity C-reactive protein (hsCRP) post acute coronary syndrome (ACS) may help identify patients at higher risk for morbidity and mortality Reporter: Aviva Lev-Ari, PhD, RN Original Investigation March 6, 2019 Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary […]